New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;ESV;R;WBMD;SPW;BSX;CVS;TER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
08:31 EDTCVSCVS Health enters into clinical affiliations with two regional health systems
Subscribe for More Information
07:56 EDTRRyder says natural gas truck fleet surpasses 30M miles
Subscribe for More Information
January 26, 2015
08:52 EDTBSXCourt ruling likely to be positive for Boston Scientific, says Bernstein
Subscribe for More Information
05:14 EDTSNYRegeneron, Sanofi announce BLA for Praluent accepted for priority review by FDA
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the Biologics License Application, or BLA, for Praluent, alirocumab. Under the Prescription Drug User Fee Act, or PDUFA, the goal for a priority review is six months, for a target action date of July 24. Alirocumab is an investigational monoclonal antibody targeting PCSK9 that is intended for the treatment of patients with hypercholesterolemia. The BLA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. Earlier this month, the companies announced that the European Medicines Agency accepted for review the Marketing Authorization Application for Praluent in the European Union. The EMA and FDA have conditionally accepted Praluent as the trade name for alirocumab. The safety and efficacy of alirocumab have not been fully evaluated by any regulatory authority.
January 23, 2015
14:02 EDTBSXJPMorgan reports 5.7% passive stake in Boston Scientific
08:37 EDTESVBofA/Merrill U.S. oil & gas analysts to hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
10:05 EDTRHigh option volume stocks
Subscribe for More Information
10:03 EDTSPWOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:31 EDTBSXBoston Scientific damages in case likely to be manageable, says Wells Fargo
Subscribe for More Information
05:47 EDTBSXStocks with implied volatility movement; BSX T
Stocks with implied volatility movement; Boston Scientific (BSX) 49, AT&T (T) 20 according to iVolatility.
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
16:14 EDTSPWSPX Corp. initiated with a Buy at UBS
Subscribe for More Information
12:11 EDTESVStocks with call strike movement; DNR ESV
Subscribe for More Information
10:28 EDTCVSLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:16 EDTSNYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
10:01 EDTCVSOn the Fly: Analyst Initiation Summary
Subscribe for More Information
10:01 EDTCVSOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ashford Hospitality (AHT) upgraded to Outperform from Neutral at Credit Suisse... BAE Systems (BAESY) upgraded to Buy from Neutral at Goldman... Bazaarvoice (BV) upgraded to Outperform from Market Perform at Cowen... Becton Dickinson (BDX) upgraded to Outperform at Cowen... CVS Health (CVS) upgraded to Buy from Neutral at Goldman... Camden Property (CPT) upgraded to Outperform from Neutral at Credit Suisse... ConocoPhillips (COP) upgraded to Buy from Neutral at BofA/Merrill... Cornerstone OnDemand (CSOD) upgraded to Buy from Neutral at DA Davidson... Cree (CREE) upgraded to Overweight at Stephens... DDR Corp. (DDR) upgraded to Outperform from Neutral at Credit Suisse... EastGroup Properties (EGP) upgraded to Outperform from Neutral at Credit Suisse... Energy Transfer Partners (ETP) upgraded to Outperform from Neutral at Credit Suisse... Esperion (ESPR) upgraded at BofA/Merrill... Exxon Mobil (XOM) upgraded to Outperform from Market Perform at Wells Fargo... FXCM (FXCM) upgraded to Market Perform from Underperform at Keefe Bruyette... Fair Isaac (FICO) upgraded to Overweight from Equal Weight at Barclays... Golar LNG (GLNG) upgraded to Buy from Hold at Nordea... Gran Tierra (GTE) upgraded to Buy at Canaccord... Host Hotels (HST) upgraded to Outperform from Neutral at Credit Suisse... J.M. Smucker (SJM) upgraded to Overweight from Neutral at JPMorgan... Kilroy Realty (KRC) upgraded to Neutral from Underperform at Credit Suisse... Level 3 (LVLT) upgraded to Outperform from Market Perform at Wells Fargo... Lowe's (LOW) upgraded to Overweight from Equal Weight at Morgan Stanley... Michael Kors (KORS) upgraded to Outperform at Cowen... Netflix (NFLX) upgraded at Nomura... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ruckus Wireless (RKUS) upgraded to Outperform from Market Perform at Northland... Santander Mexico (BSMX) upgraded to Neutral from Underperform at Credit Suisse... Scorpio Tankers (STNG) upgraded to Buy at Canaccord... Sprouts Farmers Markets (SFM) upgraded to Buy from Neutral at BofA/Merrill... Strategic Hotels (BEE) upgraded to Outperform from Neutral at Credit Suisse... The Medicines Co. (MDCO) upgraded to Outperform from Market Perform at Leerink... Whole Foods (WFM) upgraded at Sterne Agee... Wolseley (WOSYY) upgraded to Neutral from Underperform at Exane BNP Paribas.
07:45 EDTTERTeradyne coverage assumed with a Neutral at Credit Suisse
Subscribe for More Information
07:37 EDTCVSCVS Health initiated with an Overweight at Stephens
Subscribe for More Information
06:05 EDTCVSCVS Health upgraded to Buy from Neutral at Goldman
Goldman upgraded CVS to Buy based on strong leverage to Rx growth and Specialty, procurement savings upside, and capital deployment optionality. Price target raised to $113 from $95.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use